Allergic reactions after vaccination: translating guidelines into clinical practice

Radice, Anna; Carli, G; Macchia, Donatella; Farsi, Alessandro

doi:10.23822/eurannaci.1764-1489.86

Cited by 15 publications

(16 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Idiopathic anaphylaxis is diagnosed through exclusion of other known causes and may mask a clonal mast cell disorder. [18][19][20][21][22][23] Non-immunological anaphylaxis was previously termed anaphylactoid reactions, but the World Allergy Organization (WAO) in 2004 suggested replacing anaphylactoid reactions with non-immunological anaphylaxis. 24 The change in terminology is to reinforce the risk and potential fatality of all types of anaphylaxis, regardless of the underlying mechanism.…”

Section: S Ec Ti On I: Vaccine-a Sso Ciated Allerg Ic Vs Non -Allerg Ic Re Ac Tionsmentioning

confidence: 99%

“…Anaphylaxis can be either immunological, non‐immunological, or idiopathic. Idiopathic anaphylaxis is diagnosed through exclusion of other known causes and may mask a clonal mast cell disorder 18–23 . Non‐immunological anaphylaxis was previously termed anaphylactoid reactions, but the World Allergy Organization (WAO) in 2004 suggested replacing anaphylactoid reactions with non‐immunological anaphylaxis 24 .…”

Section: Section I: Vaccine‐associated Allergic Vs Non‐allergic Reactionsmentioning

confidence: 99%

See 1 more Smart Citation

Vaccines and allergic reactions: The past, the current COVID‐19 pandemic, and future perspectives

Sampath

Rabinowitz

Shah

et al. 2021

Allergy

123

View full text Add to dashboard Cite

The rapid development and the launch of several novel COVID-19 vaccines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an extraordinary and remarkable accomplishment of modern science. The Pfizer-BioNTech BNT162b2 was the first vaccine to be granted temporary authorization for emergency use by the Medicines and Healthcare Products Regulatory Agency (MHRA) in the U.K for the treatment of COVID-19 on 2 December 2020. 1 Soon after, on 11 December 2020, it also received emergency use authorization (EUA) by the U.S. Food and Drug Administration (FDA). 2 EUA is a mechanism to facilitate the availability of vaccines during public health emergencies, such as the current COVID-19 pandemic. Under an EUA, the FDA may allow the use of unapproved medical products (including vaccines) to prevent serious or life-threatening disease when certain statutory criteria have been met and no adequate and/or approved alternatives are available. The authorization of BNT162b2 was followed by an EUA for a second COVID-19 vaccine, the Moderna mRNA-1273 on 18 December 2020. 3 This was followed by the authorization of mRNA-1273 for use by other regulatory agencies such as the European Commission, UK MHRA, Israel Ministry of

show abstract

Section: S Ec Ti On I: Vaccine-a Sso Ciated Allerg Ic Vs Non -Allerg Ic Re Ac Tionsmentioning

confidence: 99%

Section: Section I: Vaccine‐associated Allergic Vs Non‐allergic Reactionsmentioning

confidence: 99%

Vaccines and allergic reactions: The past, the current COVID‐19 pandemic, and future perspectives

Sampath

Rabinowitz

Shah

et al. 2021

Allergy

123

View full text Add to dashboard Cite

show abstract

“…Despite being safe, sustainable, and effective, vaccines could be accompanied with risks of coincidental adverse events, which may not necessarily have a causal relationship with their use [ 11 ]. For candidate vaccines, safety assessment is integrated into all stages of the clinical development pipeline, and once they are deployed into the population [ 12 ].…”

Section: Introductionmentioning

confidence: 99%

Active Surveillance of Adverse Events in Healthcare Workers Recipients After Vaccination with COVID-19 BNT162b2 Vaccine (Pfizer-BioNTech, Comirnaty): A Cross-Sectional Study

Ripabelli

Tamburro

Buccieri³

et al. 2021

J Community Health

View full text Add to dashboard Cite

In this cross-sectional study, adverse events after the first and second dose of BNT162b2 mRNA (Pfizer-BioNTech, Comirnaty) vaccine against coronavirus disease 2019 were investigated among employees of clinics in central Italy. A 42-items questionnaire was administrated to vaccine recipients. Adverse events were classified based on severity and occurrence as reported in the literature. A descriptive/univariate analysis using Chi-square or Fisher’s Exact tests was performed. Odds ratio (OR) and 95% confidence intervals were calculated to assess risk factors. 340 individuals (61.5% females; median age 49 years) participated. Adverse events were reported by 279 (82%) and 281 (82.6%) individuals as induced by the first and second dose, respectively. Mild reactions were mainly reported (80.9% and 80.3%), followed by moderate (11.8% and 37.1%) and severe (3.8% and 4.7%). Adverse events were identical to those already described as very common (81.8% and 80.6%), although vaccine-coincidental events not cited in the literature were reported by 6% and 15.6% following each dose. Age ≤ 55 years was a risk factor for any adverse event after each injection (ORs: 2.942 and 2.818), as well as female sex for those mild (ORs: 1.856 and 2.818) and common (ORs: 3.452 and 2.145). Findings were consistent with national reports as most of the adverse events were mild and associated with female sex and young age, while investigations are needed for reactions not described elsewhere. Data are useful to support the vaccine safety profile, also because largely targeted healthcare personnel more skilled than general population in self-diagnosis of health-related issues.

show abstract

“…Es más frecuente que estas reacciones se deban a excipientes, por ejemplo estabilizadores, adyuvantes, conservadores, antibióticos, sustancias residuales del medio de cultivo, látex. 19,20 Estabilizadores Gelatina (mediada por IgE) La gelatina es un producto derivado del colágeno parcialmente hidrolizado de mamíferos (porcinos o bovinos) o peces.…”

Section: Componentes De Las Vacunas Que Pueden Provocar Anafilaxiaunclassified

Anafilaxia causada por vacunas

Perea-Valle

Delgado-Aguirre²,

Villafuerte-Domínguez³

et al. 2022

RAM

View full text Add to dashboard Cite

A pesar de la difícil situación que se enfrenta con la actual pandemia de COVID-19, la ciencia ha tenido un desarrollo exponencial. Si bien la inmunización contra esa enfermedad ha sido posible gracias a ello, desafortunadamente se ha acompañado de desinformación y mitos en torno a su fabricación y reacciones adversas. Por tal razón, es importante revisar una de las reacciones adversas a vacunas más temidas para el personal de salud y la población general, la anafilaxia. La anafilaxia se define como una reacción alérgica aguda y sistémica que puede poner en riesgo la vida; se asocia con distintos mecanismos inmunológicos, factores desencadenantes y manifestaciones clínicas. Su diagnóstico puede ser confuso, por lo que se han establecido diferentes criterios. Todas las inmunizaciones tienen el potencial de desencadenar anafilaxia, aunque este evento es poco frecuente. Respecto de las vacunas contra el coronavirus SARS-CoV-2, en Estados Unidos se ha reportado una tasa de anafilaxia de 1:200 000 para la vacuna Pfizer-BioNTech, y de 1:360 000 para la vacuna de Moderna. Al igual que un fármaco, las vacunas pueden presentar efectos adversos mediados por mecanismos de hipersensibilidad, pero a diferencia de lo que sucede con los medicamentos, el principio activo rara vez es el responsable; es más frecuente que las reacciones indeseadas se deban a los excipientes. La sospecha de una anafilaxia secundaria a su aplicación obliga a una oportuna referencia y a un correcto diagnóstico, tanto para el beneficio del paciente como para mejorar el perfil de seguridad de la vacuna.

show abstract

Allergic reactions after vaccination: translating guidelines into clinical practice

Cited by 15 publications

References 27 publications

Vaccines and allergic reactions: The past, the current COVID‐19 pandemic, and future perspectives

Vaccines and allergic reactions: The past, the current COVID‐19 pandemic, and future perspectives

Active Surveillance of Adverse Events in Healthcare Workers Recipients After Vaccination with COVID-19 BNT162b2 Vaccine (Pfizer-BioNTech, Comirnaty): A Cross-Sectional Study

Anafilaxia causada por vacunas

Contact Info

Product

Resources

About